ArticleEmerging infectious diseases2020
Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States.
Article in Emerging infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 69 citations in OpenAlex.
- Development of the Physical Distancing Scale for COVID-19 Avoidance (PDS-C19©) in immunocompromised and non-immunocompromised individuals and its validation in the EAGLE Study.Journal of patient-reported outcomes · 2026Article
- Article
- Influenza Vaccines for Persons Who Are Immunocompromised: A Scoping Review of the Literature.Open forum infectious diseases · 2026Article
- Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2026Article
- Immunocompromised Status Definition in Observational Studies Using Electronic Health Records: A Scoping Review and a Proposal for a Phenotype Identification Algorithm.Pharmacoepidemiology and drug safety · 2026Article
- Changing Prevalence of Immunocompromising Conditions in Patients Hospitalized with Severe Acute Respiratory Infection in Europe: Insights from the COVIDRIVE Study.Journal of epidemiology and global health · 2026Article
- Review
- Successful management of severeFrontiers in medicine · 2026Article
- Innovation in active and passive immunisation of people who are immunocompromised: a call to action.The Lancet. Infectious diseases · 2026Review
- Assessing the association of physical distancing to avoid COVID-19 with health-related quality of life in immunocompromised adults: results from the cross-sectional observational EAGLE study.BMJ public health · 2026Article
- Evaluating the generalizability of commercial healthcare claims data.American journal of epidemiology · 2025Article
- Assessing the safety and efficacy of prescribing psychologists in New Mexico and Louisiana.The American psychologist · 2025Article
- A Network for Advancing Prevention and Treatment of Infections Among Immunocompromised Individuals.JAMA network open · 2025Article
- Risk of Long COVID in hospitalized individuals treated with remdesivir for acute COVID-19.Scientific reports · 2025Article
- Paediatric Acute Invasive Fungal Sinusitis Outcomes Over a 13-Year Period.Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery · 2025Article
- Chikungunya in a pediatric cohort: Asymptomatic infection, seroconversion, and chronicity rates.PLoS neglected tropical diseases · 2025Article
- Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018.Human vaccines & immunotherapeutics · 2024Article
- Remdesivir-Associated Survival Outcomes Among Immunocompromised Patients Hospitalized for COVID-19: Real-world Evidence From the Omicron-Dominant Era.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Not the Silver Bullet: Uncovering the Unexpected Limited Impacts of Silver-Containing Showerheads on the Drinking Water Microbiome.ACS ES&T water · 2024Article
- Persistent bloodstream infection in children: examining the role for repeat blood cultures.Journal of clinical microbiology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
Abstract
Increasing use of immunosuppressive biologic therapies poses a challenge for infectious diseases. Immunosuppressed patients have a high risk for influenza complications and an impaired immune response to vaccines. The total burden of immunosuppressive conditions in the United States, including those receiving emerging biologic therapies, remains unknown. We used the national claims database MarketScan to estimate the prevalence of immunosuppressive conditions and risk for acute respiratory illnesses (ARIs). We studied 47.2 million unique enrollees, representing 115 million person-years of observation during 2012-2017, and identified immunosuppressive conditions in 6.2% adults 18-64 years of age and 2.6% of children <18 years of age. Among 542,105 ARI hospitalizations, 32% of patients had immunosuppressive conditions. The risk for ARI hospitalizations was higher among enrollees with immunosuppression than among nonimmunosuppressed enrollees. Future efforts should focus on developing improved strategies, including vaccines, for preventing influenza in immunosuppressed patients, who are an increasing population in the United States.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.